Navigation Links
A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
Date:9/19/2012

esponder patients chronically infected with HCV genotype 1a.

Additional information about this study will be posted on http://www.clinicaltrials.gov

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir (TMC435), a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Research & Development Ireland.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia. and today Medivir has a broad product portfolio with prescription pharmaceuticals in the Nordics.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, is launched in collaboration with GlaxoSmithKline to be sold OTC under the brand name ZoviDuo in Europe, Japan and Russia.

Medivir's IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Direct: +46-8-440-6550 or:
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
4. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
5. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
6. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
7. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
9. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
10. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... experience in multi-GPU high-performance computing systems designed ... scientists, engineers and researchers with a GPU-based ... (PSC), which will be shown at the ... Conference, the top international conference for high ...
... the First Time , ... San Diego, CA (PRWEB) ... a regenerative medicine company developing solutions based on the products of ... of Regenerative Medicine conference, taking place November 17-18, 2008 in London. ...
... Henderson LLP, one of Canada,s Largest Law firms, has implemented a ... The firm has leveraged FileTrail Web Services to integrate physical records ... the Firm,s 2,000 employees. , ... San Jose, CA ...
Cached Biology Technology:BOXX Personal Supercomputer for Research Scientists Featured at SC08 2Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine 2Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine 3Gowlings Adopts RFID and Unifies Practice Management 2Gowlings Adopts RFID and Unifies Practice Management 3Gowlings Adopts RFID and Unifies Practice Management 4
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... Using data from over 18,000 patients, scientists have ... involved in Parkinson,s disease, including six that had ... Nature Genetics , was partially funded by ... by scientists working in NIH laboratories. , "Unraveling ... understanding the multiple mechanisms involved in this complex ...
(Date:7/25/2014)... and some of the smoke from those fires is drifting ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua satellite ... over the Great Lakes region of the United States. ... 23, 2014 (first image feature highlighted below) clearly shows the ... In the image, it is over Manitoba and parts ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... University Bloomington scientists will use knowledge about methane production ... in on evidence for similar, carbon-based microbes that could ... Saturn,s Enceladus. The three-year project, funded by a ... for Exploring Planets (ASTEP) program, will be led by ...
... are being found increasingly in the environmentand in environmental ... properties, especially as antibacterial and antifungal agents, silver nanoparticles ... industrial and consumer products. This, in turn, has raised ... the environment. Now a new research paper* adds an ...
... on the long-awaited era of the "$1,000 genome" a time ... deciphered for about that amount compared to nearly $1 million ... of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, raises the ... estimate, is necessary to analyze that genetic data so it can ...
Cached Biology News:NASA project eyes climate change in Greenland -- with a third eye on Mars 2NASA project eyes climate change in Greenland -- with a third eye on Mars 3Silver cycle: New evidence for natural synthesis of silver nanoparticles 2
... Data System (CDS) now provides integrated ... data processing and reporting for the ... The companys innovative HPLC instrument has ... of Thermo Scientific Hypersil GOLD 1.9 ...
...
...
... Exiqon's miRCURY LNA technology enables sensitive ... Northern blotting. miRCURY LNA Detection probes have ... specific and sensitive detection of miRNAs. Due ... miRCURY LNA probes less than 1/10 the ...
Biology Products: